GSK’294 is designed to deliver long-acting suppression of IL-5 in severe eosinophilic asthma patients
News
UK approval for Daiichi Sankyo’s cholesterol-lowering treatments
In the UK, over seven million people are affected by cardiovascular disease
NICE backs AstraZeneca’s Calquence for CLL
Recommendation offers new chemotherapy-free treatment options for these patients
UK gene therapy hub network awarded £18m in funding
Hubs will be located at King’s College London, NHS Blood and Transplant in Bristol and the University of Sheffield
HRA Pharma Rare Diseases funds online hub for Cushing’s Syndrome
Cushing’s Syndrome is rare and severe condition caused by prolonged high levels of cortisol in the blood
Priority review for Merck & Co’s belzutifan in rare kidney cancer subset
Belzutifan is a potential treatment for von Hippel-Lindau disease-associated renal cell carcinoma
Lilly’s mirikizumab hits primary endpoint in ulcerative colitis study
Patients treated with monoclonal antibody achieved clinical remission at week 12
GSK, Medicago launch late-stage trial of plant-derived COVID-19 vaccine
Vaccine candidate has previously been granted FDA fast track designation
Finalists from last year’s CROY share their highlights
Clinical Researcher of the Year – The Americas finalists reveal their positive experiences with the 2020 competition.
Further work needed to develop NHS health technology approaches, report finds
NHS rolled out new technology at an ‘incredible pace’ during pandemic
Antiverse raises £1.4m to bolster AI antibody drug discovery platform
Company is focused on identifying therapies for cancer, heart and lung diseases
Frontline charities sign open letter backing COVID-19 vaccination drive
Over 20 charities are encouraging people with underlying conditions to receive a jab
Lilly’s donanemab slows decline in Phase II Alzheimer’s study
Alzheimer’s Drug Discovery Foundation says results are ‘promising’
Cambridge Sleep Sciences and Parkinson’s Concierge to test sleep device in Parkinson’s disease
SleepHub device to be assessed in people with Parkinson’s associated sleep issues
Novavax’s COVID-19 vaccine ‘highly’ effective against UK variant
Vaccine found to have an overall vaccine efficacy of 89.7% in Phase III trial
